$5.5 billion is chasing longevity. Almost none of it is built for an Australian woman.

Between February and April 2026, investors put US$5.5 billion into 25 companies working on how we age. Senior care platforms, Alzheimer's antibodies, sleep apnoea devices, AI cardiovascular monitoring and Medicare advocacy services. WHOOP, the wrist-worn tracker, is now valued at US$10.1 billion. Solace Health, which helps Americans navigate Medicare, hit unicorn status. The US Centres for Medicare and Medicaid Services has opened US$100 million in grants for lifestyle medicine. The Trump administration has set a three-year FDA pathway for AI agents that provide round-the-clock clinical monitoring, beginning with cardiovascular care.

The capital and momentum are real. Almost none of what is being built is aimed at the woman who will end up paying for it, and almost none of it is being built in Australia. The translation will come, mostly via the TGA following the FDA, and via private operators here selling whatever the US market validates.

Where the money went

Of the 25 companies that raised money in this period, two were specifically focused on women's health through hormonal transitions. Prickly Pear Health raised US$600,000 for voice AI and wearables supporting women's brain health through perimenopause and menopause. Coral, a Canadian virtual care platform for menopausal women, raised CA$4 million.

Under US$5 million combined. Out of US$5.5 billion. Less than 0.1 per cent of the capital deployed.

For context, Silicon Valley Bank's most recent women's health report puts total global venture funding for women's health at US$2.6 billion across 2024 as a whole — its record year. The longevity capital deployed in a single 12-week window in 2026 is more than double that record annual total.

The rest of the money targets general longevity infrastructure: drugs for neurological disease, devices for sleep apnoea, AI for cardiovascular monitoring, home care platforms for over-65s, primary care for Medicare-eligible adults. Useful work, but none of it addresses the specific physiological, metabolic and hormonal reality of being a woman in her 50s in Australia trying to stay strong, sharp and capable for the next 30 to 40 years.

What this looks like in Australia

Three shifts will reach Australian women within the next few years.

Clinical AI will be fast-tracked. The FDA's three-year pathway for agentic AI in cardiovascular care will set the international template. The TGA's software-as-a-medical-device framework will track that template, as it has tracked previous FDA clearances. Within five years, AI-assisted health monitoring will be routine, and Australian women will encounter it first through private cardiovascular and metabolic clinics, not the public system.

Lifestyle medicine is getting institutional backing offshore. The CMS MAHA ELEVATE program funds whole-person, prevention-oriented care across physical, mental and nutritional health, with US$100 million across two cohorts. There is no Australian equivalent. The MBS does not pay for the integrated preventive care being modelled in the US. Australian women who want it pay privately, typically AU$2,000 to AU$8,000 a year out of pocket — based on current market rates for hormone testing, body composition analysis, biological age panels and lifestyle coaching that the US is now experimenting with at scale.

The data infrastructure is consolidating. Wearables, continuous glucose monitors, biological age tests and home diagnostics are merging into something that resembles a personal longitudinal health record. The tools are available. What is missing for Australian women is a framework for using them that is grounded in evidence, sized to female physiology, and not priced like a private health package.

Three uncomfortable questions

Before investing in this new direction for medical interventions or believing the marketing hype, the longevity sector deserves three sceptical reads. To ground what is, by now, a personal view formed from twenty years in this field, that we may have been sold a pup, I have drawn the research in this article from inside geroscience rather than from the biohacking or grant-seeking fringes.

First, the proof question. The FDA does not currently recognise ageing as a drug indication. The TAME trial, designed by Justice and colleagues to provide a template for testing geroprotective drugs, still hinges on time-to-event outcomes for cardiovascular events, cancer, cognitive decline, dementia and death because no biomarker has been validated as a surrogate for ageing itself (Justice et al. 2018; Newman et al. 2023). Telomere length, methylation clocks and inflammatory markers correlate with ageing. None of them is accepted as a regulatory endpoint. A discipline that cannot yet prove its interventions extend healthspan in humans and that depends on commercial channels for delivery finds itself in a position familiar to anyone who has watched the supplement industry claim what the evidence does not support.

Second, the algorithm question. The most-cited longevity tools rely on epigenetic clocks. Higgins-Chen and colleagues showed that technical noise produced deviations of up to nine years between replicate measures of the same blood sample using the canonical clocks (Higgins-Chen et al. 2022). A 2024 Nature Aging analysis estimated that two-thirds to three-quarters of the accuracy underpinning the original Horvath clock could be driven by stochastic processes (Tong et al. 2024). The implication is direct. A population-level statistical model cannot reliably predict an individual woman's epigenetic trajectory. Her exposome is too noisy, her biology is too plastic, and her clock outputs are too unstable to drive the kind of personalised intervention being marketed in their name.

Third, the cost question. Goldman and colleagues (2013) have modelled the economic case for a longevity dividend, arguing that delayed ageing produces enormous social value. Separately, Olshansky has repeatedly argued that effective biomedical anti-ageing interventions will be expensive, that demand will come disproportionately from the better educated, wealthier and already healthy and that this would amplify existing socioeconomic and health inequalities (Olshansky 2018). The current commercial longevity sector is doing exactly that. Australian access to the integrated care being funded in the US runs through private clinics charging four-figure annual fees. The average Australian woman, working, raising children, supporting ageing parents, will not see this money.

What this means for SLOWageing

I started building tools for women's healthy ageing before COVID, including a published AI chatbot pilot with an Italian research centre in 2018. The project stalled, and since then the landscape has shifted in ways that sharpen the original thesis.

Women over 50 are the highest-leverage cohort for long-term health behaviour change. They run households, partners, ageing parents and communities. When they change, the system around them shifts. The tools available to them now are clinical, written for practitioners, motivational, written for Instagram, or commercial, written to sell supplements. What is missing is a structured, evidence-based approach to lifespan management, sized to individual biology, and delivered in a format that respects the intelligence of the woman using it.

That is what our SLOWageing project is building. The Fast Living, Slow Ageing book rewrite is underway. We are rebooting our eating program, a body baseline risk tool, and our behaviour change model (which has researched personality and values in women and their impact on their health decision-making). The sector data tells me we are building in the right lane. The capital has not arrived in it yet.